哈乐联合荡石胶囊治疗输尿管中下段结石的临床研究  

Harnal combined with Dangshi capsules for treatment for middle-lower ureteral calculi

作　　者：李超[1] 任文彪[1] 陈金波[1] 陈诚[1] 程序[1] 朱冶文 祖雄兵[1] 

机构地区：[1]中南大学湘雅医院泌尿外科,湖南长沙410008

出　　处：《中国现代医学杂志》2017年第1期103-106,共4页China Journal of Modern Medicine

摘　　要：目的探讨哈乐联合荡石胶囊治疗输尿管中、下段结石的临床效果及安全性。方法将128例输尿管中、下段结石患者随机分为哈乐组、荡石组和联合组3组。哈乐组43例患者,口服哈乐胶囊,0.4 mg/次,1次/d;荡石组40例患者,口服荡石胶囊,1.8g/次,3次/d;联合组45例患者同时口服哈乐及荡石胶囊。嘱3组患者多饮水,适量活动,比较3组患者4周内结石排出时间、结石排出率、肾绞痛发生率、外科干预率及不良反应发生率。结果联合组结石排出时间为(6.2±3.5)d,结石排出率为75.6%,肾绞痛发生率为13.3%,外科干预率为15.6%。其与哈乐组及荡石组比较,差异有统计学意义(P<0.05)。而3组不良反应发生率比较,差异无统计学意义(P>0.05)。结论哈乐联合荡石胶囊较单独用药可明显提高输尿管中、下段结石排出率,缩短排出时间,减少肾绞痛发生率和外科干预率,且未增加不良反应发生率,是治疗输尿管中、下段结石的一种安全而有效的方式,值得临床应用和推广。Objective To investigate the clinical efficacy and safety of Harnal combined with Dangshi capsules in the treatment of middle-lower ureteral calculi. Methods Totally 128 cases of middle-lower ureteral calculi were randomly divided into three groups, i.e. Harnal group, Dangshi group and combination group. The 43 patients in the Harnal group received Harnal capsules orally, 0.4 mg/time, once a day; the 40 patients in the Dangshi group received Dangshi capsules orally, 1.8 g/time, 3 times a day; the 45 patients in the combination group received both Harnal and Dangshi capsules orally. Three groups of patients were exhorted to drink more water and have appropriate activity. The stone discharge time within 4 weeks, stone removal rate, incidence of renal colic, surgical intervention rate and incidence of adverse reactions were compared among the 3 groups. Results In the combination group, the time of stone removal was （6.2 ±3.5）d, the stone removal rate was 75.6%, the incidence of renal colic was 13.3% and the surgical intervention was 15.6%, which were significantly different from those of the Harnal group and the Dangshi group （P〈 0.05）. There were no significant differences in the incidence of adverse reactions among the three groups （P〉 0.05）. Conclusions Harnal together with Dangshi capsules can significantly improve the removal rate of ureteral calculi, shorten the average discharged time, and decrease the incidence rate of renal colic and surgical intervention, but the adverse reaction rate is not significantly increased. The treatment is a safe and effective way to treat middle-lower ureteral ealcufi. It is worthy of clinical application and promotion.

关 键 词：输尿管中下段结石 哈乐 荡石胶囊 药物联合治疗 

分 类 号：R693.4[医药卫生—泌尿科学]